Leishmaniasis
Material: | Antibody demonstration: 2 ml serum (external service); PCR: Tissue sample/bone marrow, 5 ml EDTA blood, skin biopsy (external service); Pathogen demonstration: Visceral leishmaniasis (Kala-Azar): Puncture specimen from bone marrow, lymph nodes, if applicable tissue sample of the organs concerned or from the liver. Cutaneous leishmaniasis: Scrape off the edges of the lesions (at the border to the healthy tissue) with a scalpel, whereby priority is given to the most recent lesion, and bring the material onto several microscope slides, which have to be sent in air-dried. |
Methods: |
Ligandenassays → Immunfluoreszenzassay (IFA) Amplifikationsverfahren → Real-time-PCR Mikroskopie → Hellfeldmikroskopie Agglutinationsteste → Indirekte Hämagglutination | Criteria for evaluation | IHA: < 1:32 titer |
Indication | Suspicion of cutaneous or visceral leishmaniasis |
Please note | Leishmaniasis is endemic in South America and some African and Asian countries. Furthermore, infections are possible in the whole Mediterranean. Transmission is by the bite of the sandfly. Visceral leishmaniasis (Kala-Azar): (L. donovani), incubation time varies (3 weeks up to 18 months). Hepatosplenomegaly fever and pancytopenia of unknown origin in patients from endemic areas. Cutaneous leishmaniasis: Chronic granulomatous ulcerations of the skin, mostly self-healing. Mucocutaneous leishmaniasis (Espundia): Severe ulcerations of the mucous membranes in the mouth, nose and pharyngeal area lasting weeks to years, probably caused by lymphatic or hematogenic metastasizing of the parasite. Antibodies are detectable in both, visceral leishmaniasis (Kala-Azar) as well as the various cutaneous forms of leishmaniasis. However, a negative serological result does not rule out cutaneous leishmaniasis. Further information can be found at: www.rki.de |
External services | ja MVZ Diamedis Diagnostische Medizin Sennestadt |
Accredited | ja |
More Results for the letter L
- Lipometabolism diagnostics (LIPID)
- fat metabolism diagnostics
- Lipoprotein (a) = Lp (a) (LPA)
- Listeriosis (KLIST, LISMON)
- Listeria monocytogenes
- Lithium (LI)
- LKM autoantibodies (LKM)
- autoantibodies to liver and kidney microsomes
- LMA autoantibodies (LMA)
- Liver membrane antigen autoantibodies
- Lorazepam (LORA)
- Lormetazepam (LORM)
- LSD (LSDU)
- Lysergic acid diethylamide
- Lupus coagulant activity (LUPAK)
- Lymphocyte differentiation (LYMPD, LYMPDG, TREG, TAKT)
- Immune status
- Lysozyme (LYSOZ)